Carmela R. Abraham, Ph.D., devoted her entire career to the study of aging, neurodegeneration and Alzheimer’s disease (AD). She obtained her B.Sc. in Biology from Tel Aviv University and Ph.D. in Neuroscience from Harvard University. Dr. Abraham’s research is both basic and translational. She studies ways to protect the nerve cells that die in age-related diseases and, thus, prevent brain dysfunction and cognitive decline. For the past over forty years she has been studying mechanisms leading to brain aging and neurodegenerative diseases and developing treatments for these conditions. Her group discovered that the life-extending and cognition-enhancing Klotho protein, whose levels decrease with age, is neuroprotective, anti-oxidative and anti-inflammatory. In mouse models of AD, MS and ALS, increasing the levels of Klotho improved the outcomes of these diseases. Boosting Klotho levels is beneficial for extending health span and lifespan, and more specifically for treating cancer, kidney disease, metabolic syndrome and neurodegeneration.
Dr. Abraham is exploring various modalities to elevate the Klotho protein, presently as Chief Science Officer at ADvantage Therapeutics, Inc. and formerly as a Boston University School of Medicine (BUSM) Professor. Prior to joining ADvantage, Carmela was a Professor in the Departments of Biochemistry and Pharmacology & Experimental Therapeutics at BUSM. She is a co-founder of Klogenix (formerly Klogene).
